๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca112 Eli Lilly and Company97 AbbVie74 Merck Sharp & Dohme LLC62 Janssen Research & Development, LLC48
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Arizona

2233 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
NCT06872684Aneurysm, Aneurysm, Intracranial
Stryker Neurovascular
Not applicable
183
Arizona, California, Florida, Kansas, Massachusetts, New York, Ohio, Oregon
2025-06-20
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Active, closed
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT06912633Retinitis Pigmentosa
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
Long-term Characterization of GOREยฎ TAGยฎ Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Arizona, California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts
2025-06-19
Recruiting
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT06850623Locally Advanced Pancreatic Adenocarcinoma
DrugModified FOLFIRINOX
EXACT Therapeutics AS
Phase 2
25
Arizona, California, Massachusetts, Michigan, Pennsylvania, Rhode Island
2025-06-19
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Active, closed
An Observational Study of Individuals With Isolated Dystonia
NCT07111663Isolated/Primary Dystonia That Affects More Than One Region of the Body
Vima Therapeutics
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan
2025-06-17
Recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Alpha Tau Medical LTD.
Not applicable
50
Arizona, California, Florida, Georgia, New York, Texas
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsVedolizumab·Risankizumab
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
RxFunction Inc.
Not applicable
200
Arizona, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2025-06-17
Active, closed
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829Knee Osteoarthritis, Synovitis of Knee
4Moving Biotech
Phase 2
129
Arizona, Illinois, Massachusetts
2025-06-17
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522Parkinsons Disease (PD)
BlueRock Therapeutics
Phase 3
102
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2025-06-17
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Active, closed
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860Alcohol-associated Liver Disease
Altimmune, Inc.
Phase 2
121
Arizona, Arkansas, California, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-06-16
Active, closed
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 4
233
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2025-06-16
Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629Epilepsy, Healthy Volunteer
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
Recruiting
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
NCT06283979Pressure Ulcer, Stage IV, Osteomyelitis
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
NCT06552169Kidney Transplantation
Singulera Therapeutics Inc.
Phase 2
34
Arizona, Illinois, Minnesota
2025-06-13
Recruiting
A Phase 2 Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation
DrugRLY-2608
Relay Therapeutics, Inc.
Phase 2
277
Arizona, Arkansas, California, Colorado, Georgia, Indiana, Iowa, Maryland
2025-06-13
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493Low-grade Upper Tract Urothelial Carcinoma
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals
Phase 1/2
20
Arizona, California, Florida, Minnesota, New York, Pennsylvania, Texas
2025-06-12
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
573
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-06-12
Recruiting
Examination of Nociscan Impact on Low Back Pain Surgical Outcomes
NCT06661850Low Back Pain
Aclarion
Observational
300
Arizona, California, Florida, Illinois, Maryland, Texas
2025-06-11
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugBI 1291583
Boehringer Ingelheim
Phase 3
1,755
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-09
Recruiting
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
NCT06971614Nonmuscle-invasive Bladder Cancer
DrugT3011
ImmVira Pharma Co. Ltd
Phase 2
160
Arizona, California, Florida, New Jersey, Ohio, Pennsylvania, South Carolina
2025-06-09
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Alabama, Arizona, Arkansas, California, Florida, Georgia, Indiana, Massachusetts
2025-06-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
DrugIrafamdastat
Celgene
Phase 2
120
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-06-09
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Azacitidine·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois
2025-06-04
Recruiting
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
NCT07038343Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Massachusetts
2025-06-04
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2025-06-04
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugSAR442970
Sanofi
Phase 2
99
Arizona, California, Florida, Georgia, Iowa, Kansas, Massachusetts, Michigan
2025-06-03
Recruiting
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
NCT06989840Acne
Sagimet Biosciences Inc.
Phase 1
128
Arizona
2025-06-03
Recruiting
DFT383 in Pediatric Participants With Nephropathic Cystinosis
NCT06910813Nephropathic Cystinosis
Novartis Pharmaceuticals
Phase 1/2
30
Arizona, California, Georgia, Pennsylvania, Texas
2025-06-02
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
Arizona, California, District of Columbia, Florida, Massachusetts, New Jersey, New York, Ohio
2025-06-01
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
DrugsGemcitabine, nab paclitaxel·TNG462·RMC-9805·RMC-6236
Tango Therapeutics, Inc.
Phase 1/2
183
Arizona, Colorado, District of Columbia, Florida, Illinois, Indiana, Iowa, Massachusetts
2025-05-31
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Active, closed
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
NCT07023731KRAS G12D Mutation, Advanced Solid Cancer
Arvinas Inc.
Phase 1/2
76
Arizona, Connecticut, Florida, Indiana, Michigan, New York, North Carolina, Ohio
2025-05-29
Active, closed
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
NCT06917404Osteoarthritis, Knee
DrugPentosan Polysulfate Sodium
Paradigm Biopharmaceuticals Ltd.
Phase 3
466
Arizona, California, Florida, Illinois, Maryland, Michigan, Nebraska, Nevada
2025-05-29
Recruiting
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644Metastatic Castration-resistant Prostate Cancer
Syncromune, Inc.
Phase 2
91
Arizona, Arkansas, California, Florida, Illinois, Kansas, Louisiana, Michigan
2025-05-29
Active, closed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093Obesity, Overweight, Chronic Low Back Pain (CLBP)
DrugRetatrutide
Eli Lilly and Company
Phase 3
586
Arizona, California, Colorado, Florida, Kansas, Louisiana, Massachusetts, Michigan
2025-05-29
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916Generalized Myasthenia Gravis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 3
231
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-05-27
Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NCT07680244Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
Carl Zeiss Meditec-Dublin CoCe
Not applicable
400
Arizona, California, Florida, Maine, Missouri
2025-05-23
Recruiting
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590Idiopathic Hypersomnia
DrugALKS 2680
Alkermes, Inc.
Phase 2
126
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-05-22
Recruiting
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Florida, Maryland, Missouri, Ohio
2025-05-22
Recruiting
MagicTouchโ„ขSirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
NCT06271590Coronary Artery Disease, Native Coronary Artery Stenosis, Cardiovascular Diseases
Concept Medical Inc.
Not applicable
1,605
Arizona, California, Florida, Georgia, Illinois, Mississippi, New Jersey, New York
2025-05-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugPF-07275315
Pfizer
Phase 2
252
Alabama, Arizona, California, Colorado, Georgia, Illinois, Kansas, Michigan
2025-05-20
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigoโ„ข Aspiration System (STRIDE II)
NCT06747117Lower Extremity Acute Limb Ischemia, LE ALI
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Massachusetts
2025-05-16
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisone·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Active, closed
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT06133387Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion
EndoQuest Robotics, Inc.
Not applicable
56
Arizona, Florida, Massachusetts, Ohio, Texas
2025-05-13
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
425
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-12
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
Active, closed
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079Osteoarthritis (OA) of the Knee
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
Recruiting
Onyxโ„ข Liquid Embolic IDE Clinical Study
NCT06742801Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer
Medtronic Endovascular
Not applicable
119
Arizona, California, Colorado, Connecticut, Illinois, Iowa, Massachusetts, Nebraska
2025-05-09
Recruiting
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
NCT06450106Prostate Cancer
SURGE Therapeutics
Phase 1
18
Arizona, Florida
2025-05-08
Active, closed
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
NCT06939283Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
Ocular Assessments in Patients Treated With Tivdakยฎ in Recurrent or Metastatic Cervical Cancer
NCT06952660Cervical Cancer
Pfizer
Phase 4
100
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kentucky
2025-05-07
Recruiting
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
NCT06959706Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1
50
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2025-05-07
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2
88
Alabama, Arizona, California, Colorado, Florida, Georgia, Maryland, Michigan
2025-05-06
Active, closed
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247Myasthaenia Gravis
Cartesian Therapeutics
Phase 3
128
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2025-05-06
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
DrugsTremelimumab·Rilvegostomig·Atezolizumab·Bevacizumab
AstraZeneca
Phase 3
1,220
Arizona, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois
2025-05-06
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805Idiopathic Pulmonary Fibrosis
Mediar Therapeutics
Phase 2
164
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-05-05
Recruiting
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962Crohns Disease
DrugsTRX103·Cyclophosphamide
Tr1X, Inc.
Phase 1/2
39
Arizona, California, Florida, Illinois, Iowa, Kentucky, Michigan, Minnesota
2025-05-05
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
DrugsBNT324·Pumitamig
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
Field Shield Wound Dressing Study
NCT07337616Burn Wounds - Partial Thickness (2nd Degree)
KeriCure Medical
Not applicable
40
Arizona, Texas
2025-05-01
Recruiting
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
NCT06942949Kidney Calculi; Ureteral Calculi
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Recruiting
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320Generalized Anxiety Disorder (GAD)
DrugABBV-932
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Active, closed
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
DrugsSTK-009·SYNCAR-001
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
NCT06836609Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Regeneron Pharmaceuticals
Phase 1/2
132
Arizona
2025-04-28
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177Cancer Weight Loss
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Active, closed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836Alzheimer Disease
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kansas
2025-04-24
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Recruiting
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
NCT06777901Peripheral Arterial Diseases
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Active, closed
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080Diabetic Macular Edema (DME)
DrugsEYE103·Ranibizumab
EyeBiotech Ltd.
Phase 2/3
1,054
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-04-16
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
NCT06866405RSV Infection
DrugRSVpreF
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
Active, closed
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065MASH
DrugAfimkibart
Hoffmann-La Roche
Phase 1
50
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-04-11
Active, closed
ASCEND CSP IDE Study
NCT06830746Heart Failure, Ventricular Arrythmia
Abbott Medical Devices
Not applicable
414
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York
2025-04-11
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Rows per page Showing 601–700 of 2233
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona?page=7

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,233 of those studies with a site in Arizona.

How many clinical trials are recruiting in Arizona?

1,120 of the 2,233 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 36 have not yet opened recruitment, 1,020 are active but closed to new participants, and 57 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.